[1] International Diabetes Federation. IDF diabetes atlas, 10th edn. Brussels, Belgium: International Diabetes Federation. 2021.
[2] Zhong XL. Diabetes mellitus survey of 300,000 in fourteen provinces and cities of China. Chin Med J, 1981; 20, 678−83. (In Chinese
[3] Li YZ, Teng D, Shi XG, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ, 2020; 369, m997.
[4] Draznin B, Aroda VR, Bakris G, et al. Cardiovascular disease and risk management:standards of medical care in diabetes-2022. Diabetes Care, 2022; 45, S144−74.
[5] Draznin B, Aroda VR, Bakris G, et al. Chronic kidney disease and risk management:standards of medical care in diabetes-2022. Diabetes Care, 2022; 45, S175−84.
[6] Draznin B, Aroda VR, Bakris G, et al. Retinopathy, neuropathy, and foot care:standards of medical care in diabetes-2022. Diabetes Care, 2022; 45, S185−94.
[7] Jia WP, Weng JP, Zhu DL, et al. Standards of medical care for type 2 diabetes in China 2019. Diabetes Metab Res Rev, 2019; 35, e3158.
[8] Gorstein J, Sullivan KM, Parvanta I, et al. Indicators and methods for cross-sectional surveys of vitamin and mineral status of populations. 2007. http://motherchildnutrition.org/nutrition-protection-promotion/pdf/mcn-micronutrient-surveys.pdf.
[9] Jia WP. Screen of chronic diabetes complications is the key for prevention and treatment. Shanghai Med J, 2009; 32, 367−8. (In Chinese
[10] Liu SW, Wu XL, Lopez AD, et al. An integrated national mortality surveillance system for death registration and mortality surveillance, China. Bull World Health Organ, 2016; 94, 46−57. doi:  10.2471/BLT.15.153148
[11] Zhao ZP, Wang LM, Li YC, et al. Provincial representativeness assessment of China non-communicable and chronic disease risk factor surveillance system in 2013. Chin J Prev Med, 2018; 52, 165−9. (In Chinese
[12] Wang LM, Gao P, Zhang M, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA, 2017; 317, 2515−23. doi:  10.1001/jama.2017.7596
[13] Armstrong T, Bull F. Development of the world health organization global physical activity questionnaire (GPAQ). J Public Health, 2006; 14, 66−70. doi:  10.1007/s10389-006-0024-x
[14] Luepker RV, Evans A, McKeigue P, et al. Cardiovascular survey methods. 3rd ed. Geneva: World Health Organization. 2004.
[15] Wilkinson CP, Ferris III FL, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology, 2003; 110, 1677−82. doi:  10.1016/S0161-6420(03)00475-5
[16] Feldman EL, Stevens MJ, Thomas PK, et al. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care, 1994; 17, 1281−9. doi:  10.2337/diacare.17.11.1281
[17] Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care, 2012; 35, 556−64. doi:  10.2337/dc11-1909
[18] Ruta LM, Magliano DJ, LeMesurier R, et al. Prevalence of diabetic retinopathy in Type 2 diabetes in developing and developed countries. Diabet Med, 2013; 30, 387−98. doi:  10.1111/dme.12119
[19] Song PG, Yu JY, Chan KY, et al. Prevalence, risk factors and burden of diabetic retinopathy in China: a systematic review and meta-analysis. J Glob Health, 2018; 8, 010803. doi:  10.7189/jogh.08.010803
[20] Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA consensus conference. Am J Kidney Dis, 2014; 64, 510−33. doi:  10.1053/j.ajkd.2014.08.001
[21] U. S. Renal Data System. USRDS 2010 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States, national institutes of health, national institute of diabetes and digestive and kidney diseases. Bethesda, 2010.
[22] De Boer IH, Rue TC, Hall YN, et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA, 2011; 305, 2532−9. doi:  10.1001/jama.2011.861
[23] Reutens AT. Epidemiology of diabetic kidney disease. Med Clin North Am, 2013; 97, 1−18. doi:  10.1016/j.mcna.2012.10.001
[24] Zhang LX, Long JY, Jiang WS, et al. Trends in chronic kidney disease in China. N Engl J Med, 2016; 375, 905−6. doi:  10.1056/NEJMc1602469
[25] Iqbal Z, Azmi S, Yadav R, et al. Diabetic peripheral neuropathy: epidemiology, diagnosis, and pharmacotherapy. Clin Ther, 2018; 40, 828−49. doi:  10.1016/j.clinthera.2018.04.001
[26] Seshasai SRK, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med, 2011; 364, 829−41. doi:  10.1056/NEJMoa1008862
[27] Gregg EW, Gu QP, Cheng YJ, et al. Mortality trends in men and women with diabetes, 1971 to 2000. Ann Intern Med, 2007; 147, 149−55. doi:  10.7326/0003-4819-147-3-200708070-00167
[28] American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care, 2003; 26, 3333−41. doi:  10.2337/diacare.26.12.3333
[29] Harding JL, Pavkov ME, Magliano DJ, et al. Global trends in diabetes complications: a review of current evidence. Diabetologia, 2019; 62, 3−16. doi:  10.1007/s00125-018-4711-2
[30] Investigation Group for Chronic Diabetic Complications, Chinese Diabetes Society, Chinese Medical Association. A nationwide retrospective analysis on chronic diabetic complications and related macrovascular diseases of in-patients with diabetes during 1991-2000. Acta Acad Med Sin, 2002; 24, 447−51. (In Chinese
[31] Zhang XX, Kong J, Yun K. Prevalence of diabetic nephropathy among patients with type 2 diabetes mellitus in China: a meta-analysis of observational studies. J Diabetes Res, 2020; 2020, 2315607.
[32] Liu F, Bao YQ, Hu RM, et al. Screening and prevalence of peripheral neuropathy in type 2 diabetic outpatients: a randomized multicentre survey in 12 city hospitals of China. Diabetes Metab Res Rev, 2010; 26, 481−9. doi:  10.1002/dmrr.1107